Last reviewed · How we verify
NCT04136002: ECLIPSE
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
trial in Colorectal Cancer in 44,467 participants. Completed in 5 August 2025.
20 March 2024
Quick facts
| Lead sponsor | Guardant Health, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 44,467 |
| Start date | 8 October 2019 |
| Primary completion | 20 March 2024 |
| Estimated completion | 5 August 2025 |
| Sites | 271 locations across United States |
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
Sponsor
Guardant Health, Inc.
Who can join
Adults 45 to 84, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The ECLIPSE (Evaluation of the ctDNA LUNAR test in an Average Patient Screening Episode) study is a prospective, observational multi-site study without randomization. The primary objective of the study is to evaluate the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect colorectal cancer in a screen-relevant, average risk population.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Current and future colorectal cancer screening strategies.
Shaukat A, Levin TR. · · 2022 · cited 329× · PMID 35505243 · DOI 10.1038/s41575-022-00612-y -
A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening.
Chung DC, Gray DM, Singh H, Issaka RB, et al · · 2024 · cited 279× · PMID 38477985 · DOI 10.1056/nejmoa2304714 -
Cell-free DNA analysis in current cancer clinical trials: a review.
Cisneros-Villanueva M, Hidalgo-Pérez L, Rios-Romero M, Cedro-Tanda A, et al · · 2022 · cited 137× · PMID 35027672 · DOI 10.1038/s41416-021-01696-0 -
Cell-free DNA approaches for cancer early detection and interception.
Medina JE, Dracopoli NC, Bach PB, Lau A, et al · · 2023 · cited 64× · PMID 37696619 · DOI 10.1136/jitc-2022-006013 -
Emerging Tests for Noninvasive Colorectal Cancer Screening.
Hanna M, Dey N, Grady WM. · · 2023 · cited 36× · PMID 36539002 · DOI 10.1016/j.cgh.2022.12.008 -
Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection.
Bruhm DC, Vulpescu NA, Foda ZH, Phallen J, et al · · 2025 · cited 34× · PMID 40038442 · DOI 10.1038/s41568-025-00795-x -
Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA.
Yaghoubi Naei V, Bordhan P, Mirakhorli F, Khorrami M, et al · · 2023 · cited 18× · PMID 37692363 · DOI 10.1177/17588359231192401 -
Epigenetic liquid biopsies for minimal residual disease, what's around the corner?
Johnston AD, Ross JP, Ma C, Fung KYC, et al · · 2023 · cited 18× · PMID 37081990 · DOI 10.3389/fonc.2023.1103797
Verify or expand the search:
- PubMed search for NCT04136002
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Guardant Health, Inc. trials
Trials by the same sponsor.
- NCT06880055 — Shield Post-Approval Study Protocol · recruiting
- NCT05935384 — SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation · recruiting
- NCT05117840 — Screening for High Frequency Malignant Disease · active not recruiting
- NCT04436393 — Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer · completed
- NCT03625557 — Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical Records · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04136002 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guardant Health, Inc.
- Last refreshed: 11 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04136002.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing